Protective and therapeutic potentials of HDL and ApoA1 in COVID-19 elderly and chronic illness patients

• Published in: Bulletin of the National Research Centre Vol. 46; no. 1; pp. 222 - 7
• Main Author: AbdelHafez, Mohamed Aly
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 28.07.2022; Springer Nature B.V; SpringerOpen
• Subjects: Anemia; Apo-A1 mimetic peptide D-4F; Apolipoproteins; Chronic illness; Chronic illnesses; Clinical trials; Comorbidity; Coronaviruses; COVID-19; Cytokines; Elderly subjects; Erythrocytes; Fatty acids; HDL-Apo-lipoprotein A1; Hemoglobin; Hemoglobin-haptoglobin-hemopexin; High density lipoprotein; Humanities and Social Sciences; Hypoxia; Illnesses; Inflammation; Lipids; Medicine and Human Genetics; Mortality; multidisciplinary; Older people; Polyunsaturated fatty acids; Review; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Structure-function relationships; Viral diseases; COVID-19; Chronic illness; Elderly subjects; ω-3 polyunsaturated fatty acids; Apo-A1 mimetic peptide D-4F; Hemoglobin-haptoglobin-hemopexin; ApoM-sphingosine-1-phosphate; costus; HDL-Apo-lipoprotein A1

Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for coronavirus disease-2019 (COVID-19). Elderly subjects, obese, and patients with chronic illnesses, are the most affected group. HDL has pleiotropic physiological functions that are affected with alteration(s)...